Drug Profile
PF 6425090
Alternative Names: Clostridium difficile vaccine - Pfizer; PF-06425090; PF-6425090; Toxoid-based Clostridium difficile vaccine - PfizerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Bacterial vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Clostridium difficile infections
Most Recent Events
- 03 Mar 2022 Pfizer completes the phase III CLOVER trial in Clostridium difficile infection (Prevention) in USA, Japan, Canada, Argentina, Australia, Belgium, Bulgaria, Chile, Colombia, Czech Republic, Finland, France, Germany, Hungary, South Korea, Peru, Poland, Portugal, Slovakia, Spain, Sweden, Taiwan and United Kingdom (IM, Injection) (EudraCT2016-003866-14) (NCT03090191)
- 01 Mar 2022 Safety and efficacy data from the phase III CLOVER trial in Clostridium difficile infections released by Pfizer
- 03 Mar 2021 PF 6425090 is still in phase III trials for Clostridium difficile infections (In the elderly, Prevention) in USA (IM) (NCT03579459)